台灣臨床試驗主持人資料庫|TPIDB

問卷

Log In

繁中 EN

TPIDB

TPIDB Outstanding PI

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD1693C00001

2013-06-01 - 2018-09-11

Phase III

Terminated6

ICD-10E11.9

Type 2 diabetes mellitus without complications

ICD-10E13.9

Other specified diabetes mellitus without complications

ICD-9250.00

Diabetes mellitus without mention of complication, Type II [non-insulin dependent type][NIDDM type] [ adult-onset type] or unspecified type, not stated as uncontrolled

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Trial Applicant
Sponsor

AstraZeneca
Trial scale

Multi-Regional Multi-Center
Update

2025/08/20

Investigators and Locations

Principal Investigator Chern-En Chiang Division of Cardiovascular Diseases

Taipei Veterans General Hospital

Co-Principal Investigator

Kang-Ling Wang Division of Cardiovascular Diseases
林幸榮 Division of Cardiovascular Diseases
Tse-Min Lu Division of Cardiovascular Diseases
Wen-Chung Yu Division of Cardiovascular Diseases
Chin-Sung Kuo Division of Cardiovascular Diseases
Shih-Hsien Sung Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Kuo-Yang Wang Division of Cardiovascular Diseases

Taichung Veterans General Hospital

Co-Principal Investigator

WEI-WEN LIN Division of Cardiovascular Diseases
梁凱偉 Division of Cardiovascular Diseases
傅家保 Division of Cardiovascular Diseases
陳冠儒 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 翁國昌 Division of Cardiovascular Diseases

Chung Shan Medical University Hospital

Co-Principal Investigator

蔡青峰 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 夏建勳 Division of Cardiovascular Diseases

CHANGHUA CHRISTIAN HOSPITAL

Co-Principal Investigator

蘇矢立 Division of Endocrinology
黃宏凱 Division of Cardiovascular Diseases
杜思德 Division of Endocrinology

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 方志元 Division of Cardiovascular Diseases

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Co-Principal Investigator

劉文浩 Division of Cardiovascular Diseases
方修御 Division of Cardiovascular Diseases
陳建仁 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator WEN-TER Lai Division of Cardiovascular Diseases

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Co-Principal Investigator

顏學偉 Division of Cardiovascular Diseases
Chun-Yuan Chu Division of Cardiovascular Diseases
Ye-Hsu Lu Division of Cardiovascular Diseases
Cheng-An Chiu Division of Cardiovascular Diseases
Tsung-Hsien Lin Division of Cardiovascular Diseases
溫文才 Division of Cardiovascular Diseases
Po-Chao Hsu Division of Cardiovascular Diseases
朱志生 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Completed

Condition/Disease

Type 2 diabetes mellitus

Objectives

A

Test Drug

Dapagliflozin

Active Ingredient

Dosage Form

Dosage

10

Endpoints

A

Inclution Criteria

A

Exclusion Criteria

A

The Estimated Number of Participants

Taiwan

128 participants
Global

27000 participants